within Pharmacolibrary.Drugs.ATC.L;

model L01XA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.28833333333333333,
    adminDuration  = 600,
    adminMass      = 0.26,
    adminCount     = 1,
    Vd             = 0.44,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Oxaliplatin is a third-generation platinum-based antineoplastic agent primarily used in combination with fluoropyrimidines for the treatment of metastatic colorectal cancer. It is widely approved and utilized today as a component of regimens such as FOLFOX.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult cancer patients receiving intravenous oxaliplatin. Typical dose 130 mg/m2 over 2 hours.</p><h4>References</h4><ol><li><p>van Haren, F, et al., &amp; Steegers, M (2020). Intravenous lidocaine affects oxaliplatin pharmacokinetics in simultaneous infusion. <i>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</i> 26(8) 1850–1856. DOI:<a href=&quot;https://doi.org/10.1177/1078155220905011&quot;>10.1177/1078155220905011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32075507/&quot;>https://pubmed.ncbi.nlm.nih.gov/32075507</a></p></li><li><p>Luo, FR, et al., &amp; Chaney, SG (1999). Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. <i>Cancer chemotherapy and pharmacology</i> 44(1) 19–28. DOI:<a href=&quot;https://doi.org/10.1007/s002800050940&quot;>10.1007/s002800050940</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10367745/&quot;>https://pubmed.ncbi.nlm.nih.gov/10367745</a></p></li><li><p>Rietveld, PCS, et al., &amp; Koolen, SLW (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 176 116820–None. DOI:<a href=&quot;https://doi.org/10.1016/j.biopha.2024.116820&quot;>10.1016/j.biopha.2024.116820</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38810398/&quot;>https://pubmed.ncbi.nlm.nih.gov/38810398</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XA03;
